Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Samenvatting: Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals has presented new data at the ESC Congress 2026, highlighting the effectiveness of RNAi-based TTR-silencing in various groups of ATTR-CM patients. This presentation underscores the company's commitment to advancing RNAi therapies for cardiovascular diseases. The findings are expected to contribute significantly to the treatment landscape for these patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam presents new data demonstrating RNAi therapy effectiveness.
  • Focus on TTR-silencing shows promise for ATTR-CM patient groups.
  • Strong emphasis on advancements in cardiovascular disease treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende bedrijf op het gebied van RNAi-therapieën heeft vandaag tijdens het congres van de European Society of Cardiology (ESC) 2026 nieuwe gegevens bekendgemaakt die de kracht van op RNAi gebaseerde genuitschakeling bij hart- en vaatziekten aantonen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in

Frequently Asked Questions

What did Alnylam present at the ESC Congress 2026?

Alnylam presented new data on RNAi-based TTR-silencing effectiveness.

What is TTR-silencing?

TTR-silencing is a therapeutic approach targeting transthyretin for treating ATTR-CM.

What is the significance of the new data?

The data highlights advancements in RNAi therapies for cardiovascular diseases.

Who is Alnylam Pharmaceuticals?

Alnylam is a leading company in RNAi therapies, focusing on innovative treatments.

ShareAdd on Google
Tags: ALNY Viatris Investor Conferences Healthcare Alnylam RNAi therapy ATTR-CM ESC Congress cardiovascular diseases
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+25%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →